# Antiplatelet Therapy and Cardiovascular Diseases

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the use of antiplatelet therapy, including aspirin, clopidogrel, and ticagrelor, in the prevention of cardiovascular events, especially in the context of percutaneous coronary intervention. It also explores the impact of genetic polymorphisms, platelet reactivity, and bleeding risk on the efficacy and safety of antiplatelet drugs. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11064 |
| Works | 263 |

## Topic papers all

Showing 15 of 263.

- [Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/aspirin-plus-clopidogrel-as-secondary-prevention-after-stroke-or-transient/)
- [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)](https://scholariq.org/papers/european-guidelines-on-cardiovascular-disease-prevention-in-clinical-practice-5/)
- [Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes](https://scholariq.org/papers/ticagrelor-versus-clopidogrel-in-patients-with-acute-coronary-syndromes/)
- [Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes](https://scholariq.org/papers/prasugrel-versus-clopidogrel-in-patients-with-acute-coronary-syndromes/)
- [2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines](https://scholariq.org/papers/2018-aha-acc-aacvpr-aapa-abc-acpm-ada-ags-apha-aspc-nla-pcna-guideline-on-the/)
- [Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial](https://scholariq.org/papers/effects-of-intensive-blood-pressure-lowering-and-low-dose-aspirin-in-patients/)
- [2023 ESC Guidelines for the management of acute coronary syndromes](https://scholariq.org/papers/2023-esc-guidelines-for-the-management-of-acute-coronary-syndromes/)
- [Standardized Bleeding Definitions for Cardiovascular Clinical Trials](https://scholariq.org/papers/standardized-bleeding-definitions-for-cardiovascular-clinical-trials/)
- [2012 focused update of the ESC Guidelines for the management of atrial fibrillation](https://scholariq.org/papers/2012-focused-update-of-the-esc-guidelines-for-the-management-of-atrial/)
- [The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI](https://scholariq.org/papers/the-timi-risk-score-for-unstable-angina-non-st-elevation-mi/)
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS](https://scholariq.org/papers/2017-esc-focused-update-on-dual-antiplatelet-therapy-in-coronary-artery-disease/)
- [Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events](https://scholariq.org/papers/clopidogrel-and-aspirin-versus-aspirin-alone-for-the-prevention-of/)
- [Cytochrome P-450 Polymorphisms and Response to Clopidogrel](https://scholariq.org/papers/cytochrome-p-450-polymorphisms-and-response-to-clopidogrel/)
- [Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-stable-cardiovascular-disease/)
- [ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article](https://scholariq.org/papers/acc-aha-scai-2005-guideline-update-for-percutaneous-coronary-intervention/)

## Topic primary papers

Showing 15 of 89.

- [Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/aspirin-plus-clopidogrel-as-secondary-prevention-after-stroke-or-transient/)
- [Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes](https://scholariq.org/papers/ticagrelor-versus-clopidogrel-in-patients-with-acute-coronary-syndromes/)
- [Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes](https://scholariq.org/papers/prasugrel-versus-clopidogrel-in-patients-with-acute-coronary-syndromes/)
- [Standardized Bleeding Definitions for Cardiovascular Clinical Trials](https://scholariq.org/papers/standardized-bleeding-definitions-for-cardiovascular-clinical-trials/)
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS](https://scholariq.org/papers/2017-esc-focused-update-on-dual-antiplatelet-therapy-in-coronary-artery-disease/)
- [Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events](https://scholariq.org/papers/clopidogrel-and-aspirin-versus-aspirin-alone-for-the-prevention-of/)
- [Cytochrome P-450 Polymorphisms and Response to Clopidogrel](https://scholariq.org/papers/cytochrome-p-450-polymorphisms-and-response-to-clopidogrel/)
- [Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction](https://scholariq.org/papers/long-term-use-of-ticagrelor-in-patients-with-prior-myocardial-infarction/)
- [Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack](https://scholariq.org/papers/clopidogrel-with-aspirin-in-acute-minor-stroke-or-transient-ischemic-attack/)
- [AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update](https://scholariq.org/papers/aha-accf-secondary-prevention-and-risk-reduction-therapy-for-patients-with/)
- [2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease](https://scholariq.org/papers/2016-acc-aha-guideline-focused-update-on-duration-of-dual-antiplatelet-therapy/)
- [Clopidogrel for Coronary Stenting](https://scholariq.org/papers/clopidogrel-for-coronary-stenting/)
- [Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes](https://scholariq.org/papers/adverse-impact-of-bleeding-on-prognosis-in-patients-with-acute-coronary/)
- [Clopidogrel with or without Omeprazole in Coronary Artery Disease](https://scholariq.org/papers/clopidogrel-with-or-without-omeprazole-in-coronary-artery-disease/)
- [Platelet Activation in Unstable Coronary Disease](https://scholariq.org/papers/platelet-activation-in-unstable-coronary-disease/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.